{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-028730","form_type":"8-K","ticker":"XFOR","cik":"0001501697","company_name":"X4 Pharmaceuticals, Inc","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.119171+00:00","generated_at":"2026-06-11T17:17:18.717809+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"X4 Pharma Q2 net loss $55.7M; WHIM NDA on track; chronic neutropenia data promising","bullets":["Net loss of $55.7M in Q2 2023 includes $29.9M non-cash warrant adjustment; cash $142.3M at June 30.","NDA submission for mavorixafor in WHIM syndrome on track for early 2H 2023; potential US approval in 1H 2024.","Preliminary Phase 2 chronic neutropenia data: mavorixafor increased ANC and enabled G-CSF dose reductions in 3 patients.","Raised ~$65M via PIPE in May 2023; post-quarter expanded debt facility to $115M with $22.5M initial drawdown.","Appointed Dr. Christophe Arbet-Engels as Chief Medical Officer; new mavorixafor composition-of-matter patent through 2038."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-028730","json":"https://secwatch.observer/filing/0001628280-23-028730.json","markdown":"https://secwatch.observer/filing/0001628280-23-028730.md","text":"https://secwatch.observer/filing/0001628280-23-028730.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501697/000162828023028730/0001628280-23-028730-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501697/000162828023028730/xfor-20230810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T17:17:18.717809+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cdf89e65c0aaa4984887d1c8af22afc896a8b319","claim":"X4 Pharmaceuticals, Inc reported financial results for the second quarter ended June 30, 2023.","evidence_excerpt":"On August 10, 2023, X4 Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results and other business highlights for the second quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828023028730/0001628280-23-028730-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}